EXHIBIT 63

From:

Jinping McCormick

To:

Brenda Vesey

CC:

David Myers; Michael Perfetto

Sent: Subject: 9/15/2011 11:05:09 PM Marketing Plan and Media Plan

Attachments:

2011 Collateral Material Development plan.xls; Actavis_Media_Plan_2011_110909a.xls; Launch

Report 9-14-2011.xls

Brenda.

I'm attaching our product promotional plan as well as media plan as we discussed earlier today.

Media Plan – details our advertising schedules and is updated every month to record actuals as well as adjustment for future insertions. Attached is a Sept update, orange color is actual for past date and planned for future date. As you can see from the schedule that we maintain Actavis presence in every month in both **print and digital** among these key trade journals which mostly target pharmacists and pharmacy buyers as audiences. We occasionally target prescribing physicians as needed, e.g. oxymorphone to promote our products. Practical Pain Management falls into this category.

Every year, we aim to develop new corporate ad to fresh the image. This year, we planned for two new ones, one is being used in ad (Green Planet, Zero Carbon, we call TREE ad).

We also did more product specific promotions this year as we discussed earlier. Fentanyl, Zolpidem and Oxymorphone are published. We did extensive promotion and media campaign for oxymorphone. We have Methylphenidate ad completed and approved, ready to go as soon as the product is approved. We are working on Amphetamine ER combo ad, near completion. We completed Banzai ad too. Product ads hinge upon how many products are approved of course.

Collateral Material Development Plan – this plan is developed for product promotions and timing. It details which products require an advertisement in trade journals, which need a sell sheet that is used by sales team but not published, and which products require neither. Launch date is from early in the year and you can see from the Launch Report that many of these products' launch schedule has been delayed.

This year, we updated the product section of the Actavis.us websites and site visits have increased since the launch of new contents.

Hope this provides some details on our effort to promote both Actavis name and products. If you would like any details, either David and I would be more than happy to assist.

Jinping

Jinping McCormick

Director of Marketing



Actavis

60 Columbia Rd. Bldg B t +1 973-889-6977 @ <u>JMCCORMICK@actavis.com</u> Morristown , NJ 07960 United States f 973-993-4319 w <u>www.actavis.com</u> Internal VoIP number t 1256977

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

MLG, CSR, RPR, CRR

Product		Ad	Sellsheet	January	February	March	April	May	June	July	August	September	October	November	Decembe
Pantaprazole			4	Launch	- 550					1 22					
Amphetamine Combo ER		1		-	Launch (tent/l	ate)									
Buprenorphine			1						N S				Launch		
Buprenorphine/Naloxone		1		in process now	Launch										
Morphine ER (Kadian)			1	already complete	d - check for updat	e	Launch		5						
Morphine ER (Avinza)	4	1 (wait)					Launch (delaye	ed)					J		
Valacyclovir			1	1			Launch								
Zolipidem ER 12.5mg/6.25mg		1	update existing						Launch 6/3/11						
Donepezil	need samples		1					Launch	N. Committee						
Diltiazem ER Caps (Tiazac)		1 (maybe)						Launch							
Ropinorole	when launching	1							Launch						
Oxymorphone ER		1	1							Launch 7/1/11					
Methylphenidate ER		1								Launch					
Doxycycline DR			+							Launch					
Levetiracetam ER Tabs			1					A-ST				Launch			
	()		1					4		Launch		Launch			

Case: 1:17-md-02804-DAP Doc #: 2251-63 Filed: 08/13/19 4 of 9. PageID #: 351475

Actavis 2011 Media Plan - 1/2/2019

1 ACTAVIS Media Scho	edule - S	eptember	9, 2011					CONFIDENTIAL				THE RESERVE OF THE	Inc This document contain	confidential information			-									
VEHICLE		Planned		ACT	IIAI			January	February	March		April	May		June	July		August		September		October	The same in	November		December
Publications ican Health & Drug Benefits	CPI	Insertions as of G/B/11	Subtotal	CPI Inse	tions Subto	otal		ino Eab Items		The second						Intel®mont lettre				SantambariOnt Irona		1	B-3-7-51	Hov/Dec Issue	5 50 5 1 7	
Circulation 30,610 Published 6x	\$6,434		\$6,434	\$6,434	, ,	6,434	Ad placed Cost	Jan/Feb Issue 56.434					Morter Ad \$6,804			July/August Issue \$6,434				Mortar AD 56,434				56,434		
S. Annahid S. An		10.3	57050				Theme Space Type	Payers Perspectives ROB A size 4/C					Harmy Ad-9 ris ROS A 92e 4/C			ROB A size 4/C				ROB A size 4/C				Nov 5th Nov 19th		
: Drug Review							IO Due Date laterial Due Date	30 00 0000	720 Tel 2014	Mar 14th Issue	20 W 10 F	AND THE MAIN	May 24th Issue	June 5th Issue	June 27th Issue	July 16th July 23rd		Aug 8th Issue	Aug 29th Issue	September 3rd September 24th Sep 12th Issue	Sel 759 224	Oct 10th Issue	Oct 25th Issue	Nov 7th Issue	Nov 21st Issue	Sec Con Sque
Circulation 45,000	\$5,750	6	\$34,500	\$5,750		23,000	Ad placed Cost	Mortar Ad 3976 Budget	Mortar Ad 95 PSp		Fentany) Ad 803 760	Morter Ad sp 750	\$5.750	\$5.750	\$5,750	Morter Ad 55.000		\$5,750	\$5,750	\$5.750	1REE 80.760	\$5,750	95.750	\$5,750	\$5,750	\$5.750
FENTANYL AD	\$23,750	1	\$23,750	\$23,750	1 52	23,750	Theme av	Standard Coop Western		CHPA Profile	CHPA-Risos	Acres State of the ters stor Paper • 9 811 ABOOS	SPECIAL FEATURE REPORT CVS	Annual Drug Wholesaler Report	NACDS Marketplace Report	Ross (SedE Strict) Caudition Health		Health Care Report First Aid Niche Products Report	Pharm Rx - bonus @ NACDS roomdrop	ECRM Report Diabetes Hypertension Cholesterol Pain Arthritis	Riv Bankra Drage + - Damarela Revines	NACOS Pharmacy Roundlable	Top 100 Chain Drug Market Report	Annual Private label Report	Cat Management Roundtable	Full-Issue Study • RX
Published be-weekly							Space Type IO Due Date	ROS HOS INC. HC. Dec 150	909 HIG see AC	Feb 24th	ASBAMS TAC - FAM Nation	ROBINS SERVICE Applific	ROB KING size 4/C April 28th	ROB KING size 4/C May 11th	ROB KING size 4/C June 1st	ACERTICALENCE LUCESTR		ROB KING size 4/C July 13th	ROB KING size 4/C Aug 7th Aug 16th	ROB KING size 4/C Aug 17th	ROBKING LES NO SEPSIN	ROB KING size 4/C Sep 14th	ROB KING size 4/C Sep 28th	ROB KING size 4/C Oct 13th	ROB KING size 4/C Oct 27th	ROB KING size 4/C Nov 21st
Drugstore Daily - NACDS	\$4,995	3	\$4,995	\$4,995	3 5	M 4,995	faterial Due Date Issue date Ad placed	199-199	49.2256	Mar 4th	746.146	Apr. 120							AND TANDS TREE(3x)		200 80					
							Cost Theme												34 995 3 Ans. WARRA Share Sales Patrosphera							
blished 3x - distributed at NACDS				1			Space Type											1	475 KH sze M		7					
tore Management						м	IO Due Date laterial Due Date Issue date	-											AM 255 AM 255					9		
Circulation 41,000 Published yearly	\$7,658	1	\$7,658	\$7,658	1 5	7,658	Ad placed Cost								Morter Ad 57-705											
							Theme Space Type								60 8 60p san 60 Dis 256 6510											
Store News	_			-		M	IO Due Date faterial Due Date Issue Date	Jan Issue	Fig. 255 Stud	Mar 14th Issue		April 1st issue	\$40 mm mag	May 30th Issue	Agen (64) June 27th Issue	Service source		Aug 1st issue	and company	Sep 19th Issue		Oct 10th Issue	Oct 24th issue	Sept State House		Dec 12th Issue
Circulation 39,563 Published 15 times/year	\$6,800	5	\$34,000	\$6,800	4 \$2	27,200	Ad Unit Cost	\$6.800	Monar Ad 95 950	\$6,800	\$6,800	56,800	Morter Ad Stratt	\$6,800	\$8,800	Martar Ad 65 800		\$8,800	Tree Ad Se 300	\$6,800		\$6.800	\$6,800	\$6,800		\$6,800 The Wai-Mart Profile
ZOLPIDEM 6.25 & 12.5 AD Fentayl - \$30,078 for all 7 pages)	\$17,706	0	80	\$17,706	0	\$0	Theme Space Type	Top Players in Retail Pharmacy ROB A size 4/C		Beyond Dispensing Mad Order, PBMs -Specially Or ROB A size 4/C	ROB A size 4/C	Supplier Shoricase ROB A size 4/C	Too Playing in Refail Playment - MACAS lense ROB Pidae IIC	Niche Brands Making a Difference ROB A size 4/C	NACDS Marketplace Issue ROB A size 4/C	Too wholeself Rocks ROB Rock 400		Specialty RX - Rite Aid Profile ROB A size 4IC	Pr Acros Recor NF205 Nave ROBA cor NO	Generics Special Report ROB A size 4/C		CVS Caremark Profile ROB A size 4/C	The Supermarket Rx Report ROB A size 4/C	Generics Special Report ROB A size 4/C		ROB A size 4/C
						M	IO Due Date faterial Due Date		ose 146 der Ored			Mar 23rd Mar 25th	April Str. April Tito	May 3rd May 5th	May 31st June 2nd	Jun 60th San 60th		July 5th July 7th	Aug Per Anjum	Aug 23rd Aug 25th		Sep 13th Sep 15th	Sep 27th Sep 29th	Oct 18th Oct 20th		Nov 15th Nov 18th
0.0000000000000000000000000000000000000	12x rate \$8,884		\$44.420	12x rate \$8.884		05,536	Ad placed Cost	Jan Issue \$8.884	Feb 1866 Montar Ad 58 984	March Issue \$8.884		Apin Issa Mortar Ad 50/864	May Issue 58,884		Jane Rasie Marter As Serbbe	July Issue \$8,884		Fugura 5048 7764 AB 50 564		Sep Issue \$8,884		Oct Issue \$8.884		Tips Stud Methylanamate #1 780 \$8,884		Decision Principal Art 760 \$8,884
Published Monthly #2 or #3	30,004	3	344,420	\$0,004	4 53	3,530	Theme	Drug Pipeline	Apdit Readiness	Brand Drug erosion due to patent expire TBD	1	Amus Span Strong	Medication Safety (REMS)		little of the Non	The Medical Home		Vaccinions Also DESERTE SUPP		Specially pharmacy		Top Independent Pharmacies		Management of Alpheimer's disease		Business Outlook for 2012/Impared Pharmacist
METHYLPHENIDATE AD							Space Type IO Due Date	ROB A size 4/C Dec 14th	908 7 Year 40 -444 / 76	ROB A size 4/C Feb14th		ADB A see 4/C Mar (Sm.	ROB A size 4/C April 14th		919 4 sea 412 Val-17th	ROB A size 4/C June 16th		-806 4 604 NO -287 NO		ROB A size 4/C Aug 16th		ROB A size 4/C Sep 15th		ROB A size 4/C Oct 14th		ROB A size 4/C Nov 16th
Membership Directory	$\overline{}$	+		-	+	M	Issue date	Decl 19th	an dit	Feb 19th		Mar Mill	April 19th		70,00	June 21st		My Str		Aug 19th Sep Issue		Sep 20th		Oct 19th		Nov 19th
Circulation TBD Published Yearly	\$3,380	31	\$3,380	\$3,380	0	\$0	Ad placed Cost Theme												9	\$3,380 Annual Issue						
							Space Type			i tati										ROB A size 4/C TBD						
	_	_	_		_	м	IO Due Date laterial Due Date issue date		Feet about				May locate					10205-260		190						Dio (6100
Circulation 52,627 Published Quarterly	\$10,523	4	\$42,092	\$10,523	3 53	31,569	Ad placed Cost		Mother Ad (\$10,603				Mortar 46 810 725					Free A.9 919-007								Tram or 8(rd Ad \$10, 523
							Theme Space Type											PAIL SALE			5					WINTER ISSUE
Foods Management			_	_		M	IO Due Date laterial Due Date Issue date		285/2000				W. C. O. C. C. C.		100 MA 1000			66 24 66 24								Oct 25
Circulation 29,000 Published yearly	\$7,658	1	\$7,658	\$7,658	, s	7,658	Ad placed Cost								Mertar Ad S7 888											
							Space Type IO Due Date								609 King and Art 5 in 390 5015											
racy Purchasing & Products		-			-	- 4	laterial Due Date Issue date			Mar issue			May Issue		65F 36					Stations				Nov Issue		Dec Issue
	\$7,795	1	\$7,795	\$7,795	, 5	7,795	Ad placed Cost Theme			\$5 567 50 Specially Pharma Article			55,567 50 ASHP MidYear Show							Tive AB 97 795 85 Demons Supplement				\$5,567.50 ASHP MidYear Show		\$5,567.50 Generics Feature Article
							Space Type			4/C cover 2			4/C cover 2							415 Govern				4/C cover 2 Oct 10th		4/C cover 2 Nov 10th
scy Tines						м	IO Due Date laterial Due Date Issue date	Jan Issue	Feb Issue	Feb 10th Feb 24th		April Issue	April 10th April 24th		June Issue	July issue		F-100-F-200-F	1005-010	Aug 24th Sept Issue	<u> </u>	Scote aug		Oct 24th		Nov 10th Nov 24th Dec Issue
Circulation 162,500 Published Monthly	9,400	3	\$28,200	9,400	2 51	18,800	Ad placed Cost	\$9,400	59.400	Monar All. 36 400		\$9,400	Mortar A a 25-EEC		\$9,400	59,400		Tree Ad \$11,233.75	Daymorphone Ad \$29.258	\$9,400		Devinorationa Ad - 180 \$29,268	TBO David to ck Jinping	\$9,400		\$9.400
OXYMORPHONE AD	\$11,234 \$29,258	- 3	200000	\$11,234 \$29,258	3	11,234	Theme 7 Space Type	ROB A size 4/C	ROB A size 4/C	Contrar National System Publishment 445		Allergy & Asthma Harvey Ad Q	SAF SAFE HEADS SOS A soc AC		Women's Health ROB A size 4/C	Digestive Health ROB A size 4/C		Oncompy Ranvey and O arthreed Soveris	GENERIC SUPP - Oncology 1 og 50, benc - 1:8W	Pain Awareness / bonus polybag with ADHD supp ROB A size 4/C		Diabetes / Pharmacist Month ROB A size 4/C		Cough & Cold ROB A size 4/C		Heart Health ROB A size 4/C
1.5							IO Due Date faterial Due Date	Dec 15th Dec 19th	Jan 15th Jan 19th	Fac time		March 15th March 20th	April-10is April-10is		May 14th May 20th	June 15th June 21st		444,55% Sale30m	my vin na Ne	Aug 16th Aug 20th		Sep 15th Sep 20th		Oct 15th Oct 20th		Nov 19th
Circulation 140 668 Published Monthly	\$9,285	0	50	\$9,285	0	\$0	Ad placed Cost	Jan Issue 59 285	Feb Issue \$9,285	March Issue \$9,285		April Issue \$9.285	May Issue \$9,285		June Issue \$9.285	July Issue \$9,285		August Issue 59,285		Sept Issue 59.285		October Issue \$9.285		190v Issue \$9.265		Dec Issue \$9,285
r sussessed intentity							Theme Space Type	Cardiology ROB A size 4/C	Urology ROB A size 4/C	Bonus distribution at the APhA Meeting - Derm ROB A size 4/C		Rheumatology ROB A size 4/C	Psychiatry ROB A size 4/C		Ad Test - Neurology ROB A size 4/C	GI disorders ROB A size 4/C		Women's Health ROB A size 4/C		Diabetes ROB A size 4/C		American Pharmacists Month - Lipids/Anti-coag ROB A size 4/C		Genatrics ROB A size 4/C		Ad Test - Respitory ROB A size 4/C
						ш	IO Due Date laterial Due Date	Dec 10th Dec 15th	Jan 10th Jan 15th	Feb 10th Feb 15th		Feb 10th Feb 15th	April 10th April 15th		May 10th May 15th	June 10th June 15th		July 15th		August 10th August 15th		Sep 10th Sep 15th		Oct 10th Oct 15th		Nov 15th
al Pain Management Circulation 45,000	\$12,682		\$12,682			12,682	Ad placed	Jan Issue	Feb Issue	March Issue		April Issue	May Issue		Juté Issue	July Issue		Deymolohone Ad Setudos		Sept issue Oxymorphone Ad		Daymoranona Ac Standar		Nov Issue 512 682		Dec issue \$12,682
Published Monthly OXYMORPHONE AD	\$18,164	1	\$18,164	310,104	\$1	18,164	\$12,682 Theme Space Type											1 Marie Sees France		C4 i pg A/C Dieed + 3				1 pg 4/L olees HUB+3		i pg 4nu pieed KUB+3
						м	IO Due Date faterial Due Date			Managa tar			May law -			Julio fear		may 25th		August 17th August 19th Sept Issue		Autom 178 Fore # 199		Oct 17th Oct 19th		Nov 17th Nov 18th
Circulation 127,619 Published monthly	\$10,500	5	\$52,500	\$10,510	2 52	21,020	Ad placed Cost	Zolpiden d 25 Ad 2010 Budgill		March Issue \$10,500	\$10,500	Mertar Ab (2x) 5 0 500	May Issue \$10,500	Jane 1993e Marter (new teglina) Ad 319 550	Core Senoval	July Issue		August Issue \$10,500		Sept Issue \$10,500		Tree Ad 200 Mg		Nov Issue \$10,500		\$10,500
ZOLPIDEM 6.25 AD ILPIDEM 6.25 & 12.5 AD	\$28,141	1	\$28,141	\$28,141	1 52	28,141	Theme				- Controls	Apreses are added 5 représent alors Commandes et	Pain Management		SENERAL PENEM SUPP SOFT PROJECTION BONGS	Respiratory Dieases		Infectious Diseases		Women's Health				Psychotropics		Gastro-enterologic
rs insertions offered: nd June in polybagged supplementi	\$13,500	1	\$13,500	\$13,500	1 \$1	13,500	Space Type (50)			ROB A size 4/C Feb 15th			ROB A size 4/C April 15th	Orda kogo kili Digirish	928 A ery dic May 109	ROB A size 4/C June 15th		ROB A size 4/C July 15th		ROB A size 4/C Aug 15th		954 Face 401 694 559		ROB A size 4/C Oct 15th		ROB KING 1 4/C + 5 B/W Nov 15th
of total	-		\$410,360		\$32	18,394 93%	faterial Due Date							88/34	Min the											Nov 22nd
Supplements	\$11,234	2	524,734	\$11 234		24,734																				
of total	211,234	2	\$24,734 6%	311,234	52	7%	1000		GEOGRAPHICS		Service and the											2011		La company		
s Newsletters enericRX - Newsletter	\$1,541.67	12	\$18,500.04	\$1.541.67	12 \$18,5	500.04		210490	More Strain	Vistor 3/30	Book 51 512	90 M	Web) 31.635	91.00 \$1.00	W/W 2.42	Note:	STS II	Hotel St. St.	100 E	194 1966	2.56	7-W- 5-Me	7(6) 31(5))2	-78% \$1,462	776÷ 51 (42	
	- 0-1.01	12	,200,04	- Total Miles	316,0					Vertical Yad x 2000		70,000 70,000 754 v 400								vertex No. + No.						Vienes miller das
Guide - Vertical Banner	-		-	-	_	+		2000m	No.	1980 Z	Wester	2000	Vote	Water	Mental	State	Methy	Note	9996	**	590	28	700	Ter	fee	

Case: 1:17-md-02804-DAP Doc #: 2251-63 Filed: 08/13/19 5 of 9. PageID #: 351476

Actavis 2011 Media Plan - 1/2/2019

	\$147.88	12	\$1,775	\$147.88	12	\$1,775	Seed Vortice (Approved CRR v COP	5146 8 Signorator 20 (200)	Style Vertical Skylenderer 100 v 1955	Very Supermore 100 x 500	2745 Venda (NASCOSH 120 V 600	5144 Venton Semeniper 120 x 300	9196 Vettok Sinsor/det 160 i 900	3/48 Virtual Seysovation 125 x 900	ST48 Vention Skykowner 100 k 900	Vental Skysorden 120 x 600	/phosi 56452/8651 1250-500	7144 72-003-56150-503 200 - 500	State Vertein Skyrolyce 190 + 950	S145 Demontal Systems 1004-100	33.45 (A.t 2.3 September) (20 x 500	State Vacant Bergemak 120 oktob	\$165 Vertical Skyperical -120 ± 600	9768 Valdes Skyserspel Helph 900	8149 - 2000ki Biyksigasi - 2004 800	9146 Vertical Elyspians (03.7900
NACOS Guide - Horizontal Banner	\$147.88	12	\$1,775	\$147.88	12	\$1,775	200-200 5045 +0-2005 500 1084-00	S149 S149 Ostobol You TORIC S0	Marter Steel Henzonte Tita 105 k 30	Rate State Halisaral fisa 100+31	State State Abertantal Yea 7/3 - St	Monte 9143 Historium Top 1784-00	Taken Taken Takensi Pos Takens	Moller 2748 Herizonta Tun 2004-80	Morean S145 Her series Fas 125 kildo	2016 Horsento Fee 758 = 90	Station Station Horsestat Top 158 / 30	Appen Appendig (160 Appendig (160 Appendig	766 5438 Pangonia Tel 1281-156	Tide Stub National Tak Sku 50	97.08 97.08 HEUREARD 7/56 1700 + 90	Stab Stab Holoshar Too Tipe v No	7165 3136 10000001725 103430	Title 5748 66043000 Title 138 4 36	51-00 51-00 Place of Million 104 - 93	Tree ICOB Nondentralities VOSTERI.
NCPA - Horizontal Banner	\$245.83	12	\$2,950	\$245.83	12	\$2,950	# 1000 mm 100 1000 mm 100 100 mm 100 100 mm 100	Bostar 8246 Istoriai Top 728 v 90	Moths 5138 Historia Tao 718 x 38	aftern 2016 Herconto Too Cas 448	Worth 3248 Helizonta Tita 108 4 30	Morth 9246 Acceptair os TSE 4780	9348 \$248 Portoolal Tab 708 + 50	Hotel 5784 Houself Tep 708 x 80	76049 5049 Hamsonia Top 124 x 90	MdRa SENA Hancontol Folio TG8:s:49	Words South Noticental Fee Mg (193)	Wester 9246 9310 Intel®i⇔ 736 is 90	Tree SOAR Microsolal Top 108 kiss	Treat 55/8 Pergorian Fact (S) 198	Ties 5046 Managema Fox 28% 98	Tree SCAR Historian Tree 106 H 95	706 3216 Hejephal Tee 708 / 30	Free 9249 Helpeublan füe 206 4.44	Tipe \$240 Hansonal Pap 724 x 56	Free Sind Hereomin Tos Tobje 90
subtotal percent of budget			\$24,999 6%			\$24,099 7%																				
Paid subtotal percent of budget			\$0 \$0 0%			\$0 \$0 0%																				
Total Budget Differences	822 0		\$420,000 \$15,359			\$420,000 \$(66,607)					AT CONTRACT		ASTON S			THE STATE OF			E Allibra		The Control of the Co			New Sew	c-symtal	New York (France)

Case: 1:17-md-02804-DAP Doc #: 2251-63 Filed: 08/13/19 6 of 9. PageID #: 351477

Actavis 2011 Media Plan - 1/2/2019

Jrl	Web	Rate Card	Rep	Rep Email	Rep#	Target Audience	Circulation	12X Rate b/w page	12X Rate 4/C page	Total 1pg 4/C + 3pg b/w
Practical Pain Managemnt	http://www. practicalpai nmanagem ent.com/	http://www. practicalpai nmanagem ent.com/sit es/default/fi les/PPM_M ediaKit_201 1b.pdf		Sean.Cunni ngham@Ve rticalHealth .com		clinicians, pharmacists	46580	\$3,225	\$5,245	\$14,920
Pain Medicine	http://www.b lackwellpubli shing.com/jo urnal.asp?re f=1526-2375		Karl Franz	KFranz@Wil ey.com	781-388- 8470	TBD	5,734			\$5,555
Pain Medicine News - A page	http://www. painmedici nenews.co m/	http://www. painmedici nenews.co m/PDF/med iaplanner.p df		alabrozzi@ mcmahonm ed.com	212-957- 5300, ext. 204	clinicians	48,134			\$19,465
The Journal of Pain	http://www.e Isevier.com/ wps/find/jour naldescriptio n.cws_home /505775/des cription#des cription	KITC AICAVIAL	Michael Targowski	m.targowski @elsevier.c om	212-633- 3693	researchers, scientiests, cliniicans	2600	\$1,245	\$2,750	\$6,485
The Journal of Pain Symptom and Pain Management		http://media kits.elsevier. com/ratecar ds/JPSM di splay.pdf	Michael Targowski	m.targowski @elsevier.c om	212-633- 3693	Anesthesiologists, neurologists, oncologists, pharmacologists, nurses, social workers, and others in clinical or academic disciplines concerned with pain and palliative care	4700	\$1,935	\$3,695	\$9,500
Anesthesiolog y News	www.anest hesiologyn ews.com	http://www. anesthesiol ogynews.c om/PDF/me diaplanner. pdf		alabrozzi@ mcmahonm ed.com	212-957- 5300, ext. 204	all Anesthesiologis ts (pain - 1,204, pediatric, critial care and cardiovasular)	44,832			\$17,965



Total Launched 7
Total Launches Remaining for : 11
TOTAL Projected Launches for 18



2011 BUDGET KPI = ?? LAUNCHES

2011 Budget Launches

Label	Product	Dosage	Brand (Company)	Strengths	MAT June 2010 IMS Sales US (\$MM)	2011 Budget Approval	Target Approval [Best Case]	2011 Budget Sales (\$000)	Mfg Country, Site	Competitors	Comments	Market Share Target (2011 budget)
Actavis Inc.	Pantaprazole	DR Tablet	Protonix (Pfizer)	20, 40mg	\$1,771	Jan-11	02/07/11	\$6,473	India, Shasun	on market: Teva, Sun; new approvals: Dr. Reddy's, Kudco, Matrix, Torrent, Wockhardt	PE expires 1/19/2011	10%
Actavis Totowa	Valacyclovir	Tablet	Valtrex (GSK)	500mg, 1000mg	\$2,018	Jul-11	04/25/11	\$4,000	India, Alathur	On market: Ranbaxy, Watson, Mylan, Roxane, Sandoz, Teva, Aurobindo, Greenstone, Northstar	Filed Jun-08. API constraints help keep price at profitable level	7%-10%
Actavis Inc.	Donepezil	Tablet	Aricept (Eisai)	5, 10mg	\$2,374	May-11	5/31/2011	\$1,052	India, Alathur	13 TA. Expect highly competitive market.	Teva lost exclusivity, but Ranbaxy can lauch with exclusivity.	7%
Actavis SouthAtlantic	Zolpidem	ER Tabs	Ambien CR (Sanofi)	12.5 mg	\$812	May-11	06/06/11	\$11,255	US, ELZ	Not FTM, Anchen launched 12/6/2010		25%
Actavis Elizabeth	Oxymorphone	ER Tabs	Opana ER (Endo)	7.5mg, 15mg	\$15	July-11	07/15/11	\$3,289	US, ELZ	approval received on 7.5mg and 15mg; TA on other strengths. Brand is	PIV, filed Jun-07, May-08	60%
Sagent	Gemcitabine	Inj	Gemzar	200mg; 1g	\$814	2011	07/25/11	\$5.3M	Romania	Teva-APP; Hospira; Watson; Pliva; Sun; Sandoz	Teva-APP launched Jan. 26, last possible date to maintain 180-day exclusivity; Act- Sagent launch date revised to July 25, 2011.	15%
Actavis Elizabeth	Levetiracetam	ER Tabs	Keppra XR (UCB)	500, 750mg	\$120	Sep-11	9/12/2011	\$622	US, ELZ	8TA - Watson, Lupin, Torrent	Launched 9/12/2011 on market formation	20%
Sagent	Paclitaxel	Inj	Taxol (BMS)	6mg/ml	\$52	2011	Sept-11	\$2.4M	Romania	Teva, Hospira, APP, Bedford, Parenta already in market. 1-2 additional competitors expected over next 1-2 years.	Approved 12/10/09, API 6 month lead time. Capacity issues at Sindan; reviewing 2011 launch dates. Revised launch date August 2011.	10-15% dependin g on strength
Actavis Elizabeth	ISMN	ER	Imdur	30, 60mg	\$77	NA	Oct-11	NA	US, ELZ	KU, WestWard, Alvergo, Qualitest	relaunch	15%
Actavis, Inc	Trimipramine	Caps	Surmontil	25, 50, 100mg	\$3	NA	Oct-11	NA	US, Epic	No generic. Teva owns the brand. Potential AG	relaunch	100%
Actavis SouthAtlantic	Methylphenidate	ER Caps	Ritalin LA (Novartis)	10, 20, 30, 40mg	\$91	Jul-11	Oct-11	\$9,524		expect 3 inlcuding Sandoz as AG post exclusivity	First to file on 20, 30, 40mg; delayed due to two Citizen Petitions. Settled with Brand	60%
Actavis Elizabeth	Amphetamine Combo ER	ER Caps	Adderall XR (Shire)	5, 10, 15, 20, 25, 30 mg	\$791	Feb 11	Dec-11	\$26,419	US, ELZ	Teva/Barr launched 4/1/09. Both are AG.	Product at UPS went short- dated. CP pending -	15%

Total Launched 7
Total Launches Remaining for: 11
TOTAL Projected Launches for 18



2011 BUDGET KPI = ?? LAUNCHES

2011 Budget Launches

Label	Product	Dosage	Brand (Company)	Strengths	MAT June 2010 IMS Sales US (\$MM)	2011 Budget Approval	Target Approval [Best Case]	2011 Budget Sales (\$000)	Mfg Country, Site	Competitors	Comments	Market Share Target (2011 budget)
Actavis SouthAtlantic	Nifedipine	ER Tabs	Adalat CC (Bayer)	90mg	\$25	Jul-10	Dec-11	\$2,144	US, ELZ	Teva; Mylan got approval on all 3 strength	Filed Dec-08; line ext to existing 30mg & 60mg.	30%
Actavis Elizabeth	Buprenorphine	Sublingu al Tabs	Subutex	2, 8 mg	\$86	Feb-11	TBD	\$6,879	US, ELZ	Market formation 10/8/09. On market - Roxane, Teva; Hi-Tech	Filed September of 2008. Awaiting RiskMap/REMS approval	25%
Actavis Elizabeth	Morphine ER	Caps	Kadian (Actavis)	10, 20, 30, 50, 60, 80, 100, 200mg	\$266	Apr-11	ready	\$29,400	US, ELZ	Patents expire Apr-10; own AG	Product ready at UPS	60%
Actavis Elizabeth	Diltiazem	ER Caps	Tiazac (Biovail)	120, 180, 240, 300, 360, 420mg	\$96	May-11	Feb-12	\$2,915	US, ELZ	Approval: Watson, KV, Apotex, Inwood (AG). KV, Apotex is out of market	Filed Dec-08;	20%
Actavis Totowa	Oxycodone	Tablet	Roxicodone	5mg	\$51	Jan-11	2012	\$1,737	US, ELZ	Mallinkrodt, Qualitest, KVK, Caraco, Corepharm	Current product short-dated; Needs fresh product from ELZ post CBE 30 filing	15%
Actavis Totowa	Oxycodone APAP	Tablets	Percocet (Endo)	7.5/325, 10/325, 7.5/500, 10/650 mg	\$451	Oct-10	2012	\$6,817	US, ELZ	Mallinkrodt, Watson, Endo Roxane, Qualitest.	Filed Oct-06. Not launching 5mg/325mg; Not getting approval on 7.5/500 & 10/625mg per FDA	10%
Actavis Elizabeth	Ropinorole	ER Tabs	Requip XL	2,4,6,8,12mg	\$54	Jun-11	2012	\$6,200	US, ELZ	FTF; Impax is known filer		50%
Actavis Elizabeth	Morphine ER	Caps	Avinza (King)	30, 60, 90, 120mg	\$144	Apr-11	2013	\$18,044	US, ELZ			50%
Actavis Elizabeth	Atomoxetine	Caps	Strattera (Lilly)	10, 18, 25, 40, 60, 80, 100mg	\$514	Nov-10	2017	\$858	US, ELZ	Approval - Actavis, Aurobindo, Zydus, Sandoz, Sun, Mylan,	Court date Dec 9, 2010	15%
Actavis SouthAtlantic	Doxycycline Hyclate DR	DR Tabs	Doryx (Warner Chilcott)	75, 100mg	\$36	Jul-11	Cancelled	\$2,506	US, ELZ	Impax and Mylan approved 12/28/2010. Four known filers:Mylan, Impax, Actavis, Mutual.		50%
Actavis Inc.	Letrozole	Tablet	Femara (Novartis)	2.5mg	\$644	Dec-11	Cancelled	\$209	Romania	Tentative approval: Roxane, Teva, Zyus, Accord (Intas), Fresenius	Patent expires 6/30/2011; Cancelled due to capacitu constrains at Sindan	10%